NR3C2 and heart failure: Once it was discovered that myocardial fibrosis could be prevented through mineralocorticoid receptor blockade [55,56], the medical community began using spironolactone therapy to improve long-term prognosis in patients with heart failure with reduced ejection fraction (HFrEF), rather than just as a potassium-sparing diuretic.